**Supplementary Table 1.** The accuracy of NITs for MASH with clinically significant fibrosis or MASLD with significant fibrosis.

|  |  |  |  |
| --- | --- | --- | --- |
| Name of NITs | Types of study | Number of participants with target condition | AUC (95% CI) or C-statistic (95% CI) |
| FIB-4[48] | Original article | 18 (17.5%) in the derivation cohort; 28 (11.5%) in the validation cohort\* | 0.89 (0.81-0.96) ## in the derivation cohort and 0.71 (0.61, 0.80) ## in the validation cohort |
| NFS[28] | Meta-Analysis | 327 (35%) \* | 0·66 (0·62–0·69) ## |
| ELF[28] | Meta-Analysis | 306 (33%) \* | 0·67 (0·63–0·71) ## |
| MACK-3[28] | Meta-Analysis | 185 (34%) \* | 0·76 (0·71–0·80) ## |
| ADAPT[28] | Meta-Analysis | 160 (36%) \* | 0·77 (0·73–0·81) ## |
| LSM-VCTE[28] | Meta-Analysis | 249 (40%) \* | 0·74 (0·70–0·78) ## |
| NIS2+TM[35] | Original article | 99 (50%) in training cohort; 929 (45.7%) in test cohort\* | 0.79 (0.72-0.85) ## in training cohort and 0.81 (0.80-0.83) ## in test cohort |
| FNI[38] | Original article | 54 (20%) in training cohort; 17 (5%), 37 (4%), and 118 (2%) in external validation cohorts\* | 0.78 (0.71–0.85) ## in derivation; 0.80–0.95## in external validation cohorts |
| MRE[41] | Meta-Analysis | 314（39.4%）\* | 0.92 (0.90-0.94) ## |
| Corrected T1 (cT1) [43] | Meta-Analysis | 157 (55.3%) \*  | 0.78 (0.74–0.82) ## |
| FAST Score[44] | Original article | 174 (50%) in derivation cohort; 277 (27%) in pooled external cohort\* | 0·80 (0·76–0·85) # |
| MEFIB[50] | Original article | 69 (29.5%) in the University of California San Diego cohort; 208 (66.2%) in the Yokohama cohort\*\* | 0.86 (0.81-0.91) ## in the University of California San Diego cohort; 0.90 (0.86-0.94) ## in the Yokohama cohort |
| acFibroMASH[46] | Original article | 58 (26.6%) in the derivation cohort; 184 (38.90%) in the validation cohort\* | 0.81 (0.75-0.87) ## in the derivation cohort; 0.80 (0.76-0.84) ## in the validation cohort |
| MAST[48] | Original article | 18 (17.5%) in the derivation cohort; 28 (11.5%) in the validation cohort\* | 0.86 (0.78-0.93) ## in in the derivation cohort; 0.93 (0.88, 0.97) ## in the validation cohort |

*Note:* \*MASH and clinically significant fibrosis; \*\*MASLD with significant fibrosis; #C-statistic; ##AUROC.

*Abbreviations*: AUROC, area under the receiver operating characteristic curve; MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; NITs, non-invasive tests.